## Anti-diabetes Agents---I: Tetralone Derivative from Juglans regia

## Tian Ying AN, Li Hong HU\*, Rong Min CHEN, Zhong Liang CHEN, Jia LI, Qiang SHEN

Chinese National Center for Drug Screening, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031


**Abstract:** A new compound, 4-hydroxy- $\alpha$ -tetralone-4-O- $\beta$ -D-[6'-O-(3'',4'',5''-trihydroxybenzoyl) glucopyranoside (1), together with a known compound, 4-hydroxy- $\alpha$ -tetralone (2), has been isolated from the roots of *Juglans regia*. 2 showed moderate bioactivity against protein tyrosine phosphatase 1B (PTP1B).

Keyword: Juglans regia, Juglandaceae, tetralone, PTP1B inhibitor.

Many cellular and biochemical studies have shown that protein tyrosine phosphatase 1B (PTP1B) plays a major role in the dephosphorylation of the insulin receptor<sup>1</sup>. Thus potent and orally active PTP1B inhibitors could be potential pharmacological agents for the treatment of Type-2 diabetes and obesity.

In our research work for natural PTP1B inhibitor from our extract bank, we found that the ethanol extract of the roots of *Juglans regia* Linn. (Juglandaceae), designated PL00269, showed strong inhibitory bioactivity against PTP1B enzyme. Using the PTP1B enzyme bioassay as a guide, chromatography of the fraction afforded a new tetralone derivative, 4-hydroxy- $\alpha$ -tetralone-4-O- $\beta$ -D-[6'-O-(3",4",5"-trihydroxybenzoyl)] glucopyranoside (1), together with a known compound, 4-hydroxy- $\alpha$ -tetralone (2)<sup>2</sup>, which showed moderate bioactivity against PTP1B, IC<sub>50</sub>= 66.7 µmol/L.

Figure 1 Structures of compound 1 and 2



Compound **1**, an optically active colorless oil,  $[\alpha]_{D}^{25}$ -43 (*c* 0.67, CH<sub>3</sub>OH), with the following spectral characteristics: IR (film) *v*: 3384, 1674, 1610 cm<sup>-1</sup>; UV (MeOH)  $\lambda_{max}$ 

<sup>\*</sup>E-mail: simmhulh@mail.shcnc.ac.cn

(log  $\varepsilon$ ): 261 (3.91), 214 (4.01) nm; positive FABMS m/z [M<sup>+</sup> + 1] 477 (corresponding to C<sub>23</sub>H<sub>24</sub>O<sub>11</sub>); NMR data see **Table 1**.

Comparing the NMR data of compound 1 (see **Table 1**) with those of 2 showed the presence of 4-hydroxy- $\alpha$ -tetralone skeleton in 1 (structure A in **Figure 1**), together with a 3,4,5-trihydroxyphenyl unit [ $\delta_{\rm C}$ : 120.8, 109.3 (x 2), 145.5 (x 2), 138.5], an unsaturated carbonyl ( $\delta_{\rm C}$ : 166.5), and a glycopyranosyl unit ( $\delta_{\rm C}$ : 102.8, 77.2, 74.3, 71.0, 75.0, 64.1). The later three units formed the structure B (**Figure 1**), which was revealed by comparing the NMR data of 1 with those of the similar compound, 1,4,8-trihydroxy-1-O- $\beta$ -D-[6'-O-(3",4",5"-trihydroxybenzoyl)] glucopyranoside, isolated from *J. mandshurica*<sup>3</sup>. Combining structure A and B formed compound 1. The equatorial orientation of H-4 was deduced from its coupling constant with the two protons at C-3 ( $J_{\rm H-4, H-3} = 6.6$ , 3.3 Hz). Therefore, the structure of compound 1 was determined as 4-hydroxy- $\alpha$ -tetralone-4-O- $\beta$ -D-[6'-O-(3",4",5"-trihydroxybenzoyl)] glucopyranoside.

No.	Н (бррт, <i>J</i> Hz)	C (δppm)	No.	Н (бррт, <i>J</i> Hz)	C (δppm)
1		197.5 s	3'	3.44, m	74.3 d
2	2.83, m; 2.45, m	34.6 t	4'	3.35 (t, 8.1)	71.0 d
3	2.39, m; 2.23, m	30.6 t	5'	3.58, m	75.0 d
4	4.99 (dd, 6.6, 3.3)	74.1 d	6'	4.64 (dd, 11.7, 2.1)	64.1 t
5	7.70 (d, 7.5)	128.6 d		4.41 (dd, 11.7, 7.2)	
6	7.57 (td, 7.5, 1.5)	133.7 d	1″		120.8 s
7	7.43 (td, 7.5, 1.5)	126.7 d	2″	7.18, s	109.3 d
8	7.89 (dd, 7.5, 1.5)	128.9 d	3″		145.5 s
9		131.8 s	4		138.5 s
10		143.1 s	5″		145.5 s
1'	4.53 (d, 7.5)	102.8 d	6	7.18, s	109.3 d
2'	3.46, m	77.2 d	7″		166.5 s

Table 1 <sup>13</sup>C NMR (CD<sub>3</sub>COCD<sub>3</sub>, 75 Hz) and <sup>1</sup>H NMR (CD<sub>3</sub>COCD<sub>3</sub>, 300 Hz) spectral data of 1

**Bioassay**: PTP1B catalytic activities were routinely measured as in literature<sup>4</sup>. Na<sub>3</sub>VO<sub>4</sub> acts as positive control (IC<sub>50</sub> =  $2\mu$ mol/L).

## Acknowledgment

This work was supported by the National Natural Science Fundation of China (30100229) and Science and Technology Development Fundation of Shanghai, China (01QB14051), and these supports are gratefully acknowledged.

## References

- 1. J. C. H. Byon, A. B. Kusari, J. Kusari, Mol. Cell. Biochem., 1998, 182, 101.
- 2. A. Fourent, A. A. Barrios, V. Munoz, R. Hocquemiller, F. Roblot, A. Cave, *Planta Med.*, **1994**, 60, 8.
- 3. Y. K. Joe, J. K. Son, J. Nat. Prod., 1996, 59, 159.
- 4. Z. Y. Zhang, J. E. Dixon, Adv. Enzymol., 1994, 68, 1.

Received 21 June, 2002